Phase I Trial of Intraperitoneal Adenoviral p53 Gene Therapy in Patients With Advanced Recurrent or Persistent Ovarian Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Contusugene ladenovec (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 02 Feb 2021 Biomarkers information updated
- 16 Nov 2007 New trial centre added.
- 17 Sep 2005 New trial record.